ABUS 2.94 - "Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg"
Would love to hear comments on this update? I still believe ABUS is a low-risk investment at under-$4 pps as a stand-alone...excluding...the absolute rocketship potential here if/WHEN it's "069-Patent" makes the 6:00 0'clock news...
Market Data 
Markets 
AI
